{"entity":{"id":"arid1a","kind":"target","name":"ARID1A","aka":["AT-rich interaction domain 1A","AT-rich interactive domain-containing protein 1A","B120","P270","C10rf4","BAF250","BAF250a","C1orf4","SMARCF1"],"tldr":"ARID1A (AT-rich interactive domain-containing protein 1A) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Colorectal cancer, Endometrial cancer and 5 more.","summary":"Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Component of SWI/SNF chromatin remodeling complexes that carry out key enzymatic activities, changing chromatin structure by altering DNA-histone contacts within a nucleosome in an ATP-dependent manner. Binds DNA non-specifically.\n\nCIViC holds 14 clinical evidence items and 0 assertions across 7 variants, naming Dasatinib, Sorafenib, Nivolumab and Pembrolizumab and others. Open Targets scores its association with cancer at 0.85 (direct and indirect evidence; datatypes literature 1.00, affected pathway 0.89, genetic association 0.57, somatic mutation 0.98). IntOGen calls it a driver in 90 cohorts (1 activating, 89 loss-of-function), covering Burkitt Lymphoma, Bladder Urothelial Carcinoma, Invasive Breast Carcinoma, Renal Clear Cell Carcinoma, Cervical Squamous Cell Carcinoma, Cholangiocarcinoma and others.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:11110","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11110"},{"label":"UniProt O14497","url":"https://www.uniprot.org/uniprotkb/O14497/entry"},{"label":"NCBI Gene 8289","url":"https://www.ncbi.nlm.nih.gov/gene/8289"},{"label":"Ensembl ENSG00000117713","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000117713"}],"tags":["cancer-genes-wave"],"related":["civic","open-targets","intogen"],"cancers":["urothelial","colorectal","endometrial","gastric","breast-cancer","lung-cancer","hcc","non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":["swi-snf-chromatin"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 6 therapies; IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 89 cohorts; CIViC holds 14 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate.","Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Ovarian Clear Cell Carcinoma; Ovarian Clear Cell Adenocarcinoma; Low-Grade Glioma, NOS."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"ARID1A","role":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:11110","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11110","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt O14497","url":"https://www.uniprot.org/uniprotkb/O14497/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene ARID1A","url":"https://civicdb.org/features/6559","note":"14 evidence items, 0 assertions, 7 variants; diseases: Ovarian Clear Cell Carcinoma, Colorectal Cancer, Ovarian Cancer, Stomach Cancer, Diffuse Large B-cell Lymphoma and 4 more (GraphQL API, CC0)"},{"label":"Open Targets ENSG00000117713","url":"https://platform.opentargets.org/target/ENSG00000117713/associations","note":"association with cancer (MONDO_0004992) 0.85; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.65, colorectal cancer 0.74, gastric cancer 0.69, oesophageal cancer 0.62, hepatocellular carcinoma 0.67, cholangiocarcinoma 0.53 (GraphQL API, CC0)"},{"label":"IntOGen ARID1A","url":"https://www.intogen.org/search?gene=ARID1A","note":"driver in 90 cohorts (Act 1, LoF 89); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0"}],"hgnc":"HGNC:11110","ensembl":"ENSG00000117713","uniprot":"O14497","entrez":"8289","biology":"Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Component of SWI/SNF chromatin remodeling complexes that carry out key enzymatic activities, changing chromatin structure by altering DNA-histone contacts within a nucleosome in an ATP-dependent manner. Binds DNA non-specifically. Belongs to the neural progenitors-specific chromatin remodeling complex (npBAF complex) and the neuron-specific chromatin remodeling complex (nBAF complex). During neural development a switch from a stem/progenitor to a postmitotic chromatin remodeling mechanism occurs as neurons exit the cell cycle and become committed to their adult state. The transition from proliferating neural stem/progenitor cells to postmitotic neurons requires a switch in subunit composition of the npBAF and nBAF complexes. Location: Nucleus (UniProt). Locus 1p36.11 (HGNC).","whereFound":["Bladder & urothelial cancer: Open Targets association 0.76 with urinary bladder cancer (MONDO_0001187); IntOGen driver in 9 cohorts (BLCA, UTUC)","Colorectal cancer: Open Targets association 0.74 with colorectal cancer (MONDO_0005575); CIViC evidence names this disease","Endometrial cancer: Open Targets association 0.72 with endometrial cancer (MONDO_0011962); IntOGen driver in 4 cohorts (UCEC)","Gastric & gastro-oesophageal junction cancer: Open Targets association 0.69 with gastric cancer (MONDO_0001056); CIViC evidence names this disease","Breast cancer: Open Targets association 0.68 with breast cancer (MONDO_0007254); IntOGen driver in 8 cohorts (BRCA)","Lung cancer: Open Targets association 0.68 with lung cancer (MONDO_0008903); IntOGen driver in 1 cohort (LUNG)"],"targetClass":"transcription","prevalence":[]},"route":"/targets/arid1a/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"},{"id":"intogen","kind":"collection","name":"IntOGen","route":"/collections/intogen/"},{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"pathway":[{"id":"swi-snf-chromatin","kind":"pathway","name":"SWI/SNF chromatin remodelling","route":"/pathways/swi-snf-chromatin/"}]}}